Database : MEDLINE
Search on : vulvar and neoplasms [Words]
References found : 7971 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 798 go to page                         

  1 / 7971 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524285
[Au] Autor:Dell EA; Miest RYN; Lohse CM; Torgerson RR
[Ad] Address:Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905.
[Ti] Title:Vulvar Neoplasms in 275 Women With Genital Lichen Sclerosus and Impact of Treatment: A Retrospective Chart Review.
[So] Source:J Eur Acad Dermatol Venereol;, 2018 Mar 10.
[Is] ISSN:1468-3083
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Lichen sclerosus (LS) is a chronic inflammatory disease most commonly affecting the genital area of women. LS-associated vulvar neoplasms are known to occur (1). Treatment of LS is thought to possibly reduce malignancy risk. However, whether medical treatment of LS can prevent vulvar neoplasms is unclear (2,3). We performed a single-institution, retrospective chart review to identify vulvar neoplasm occurrence in women with biopsy-proven genital LS and to determine whether a correlation exists between LS treatments and vulvar neoplasm occurrence. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1111/jdv.14938

  2 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29489654
[Au] Autor:Kroeber ES; Mathewos A; Wondemagegnehu T; Aynalem A; Gemechu T; Piszczan S; Timotewos G; Addissie A; Wienke A; Unverzagt S; Thomssen C; Jemal A; Kantelhardt EJ
[Ad] Address:Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University, Halle an der Saale, Germany.
[Ti] Title:Vulvar cancer in Ethiopia: A cohort study on the characteristics and survival of 86 patients.
[So] Source:Medicine (Baltimore);97(9):e0041, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Vulvar cancer (VC) is strongly associated with human papilloma virus (HPV) infections and immunosuppression (e.g., HIV). However, there is limited information on VC patient characteristics and survival in parts of sub-Saharan Africa, including Ethiopia, where chronic HPV and HIV infections are prevalent. The aim of this study is to provide a first view on VC patient characteristics in a sub-Saharan African setting.We present a retrospective analysis of records of 86 VC patients diagnosed between January 2010 and October 2015 at Addis Ababa University Hospital and other major health facilities in Ethiopia. Follow-up for vital status was obtained by telephone contact with patients or relatives. The primary endpoint was all-cause mortality.The median age of the patients was 39 (range: 20-85) years, 83% with known HIV status were positive and 81% presented with FIGO stages 2 or 3. The median follow-up time for surviving patients was 17 months (range: 0.1-65.0 months). The 1- and 2-year survival rates were 80% and 51%, respectively. Approximately 37% of patients received surgery, 38% received radiotherapy, and 33% received chemotherapy. Patients who received therapy had better survival than those who did not [adjusted hazard ratios: surgery, 0.44 (95% CI, 0.19-1.03); radiotherapy, 0.36 (95% CI, 0.14-0.90); chemotherapy, 0.42 (95% CI, 0.15-1.12)].A substantial proportion of VC patients in Ethiopia present at a late stage and receive suboptimal treatment. HIV infections appear to be a common comorbid condition. These conditions result in poor outcomes.
[Mh] MeSH terms primary: Vulvar Neoplasms/epidemiology
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Comorbidity
Ethiopia/epidemiology
Female
HIV Infections/epidemiology
Humans
Middle Aged
Neoplasm Staging
Retrospective Studies
Survival Rate
Vulvar Neoplasms/mortality
Vulvar Neoplasms/pathology
Vulvar Neoplasms/therapy
[Pt] Publication type:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000010041

  3 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27772624
[Au] Autor:Chin-Hong PV
[Ad] Address:Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA. Electronic address: peter.chin-hong@ucsf.edu.
[Ti] Title:Human Papillomavirus in Kidney Transplant Recipients.
[So] Source:Semin Nephrol;36(5):397-404, 2016 09.
[Is] ISSN:1558-4488
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Human papillomavirus (HPV) is a common infection in kidney transplant recipients. HPV causes cervical, anal, vulvar, vaginal, penile and head and neck cancers. Kidney transplant recipients have a disproportionate burden of disease given prolonged immunosuppression. Given the long pre-invasive state of precancer lesions such as cervical intraepithelial neoplasia (CIN) and anal intraepithelial neoplasia (AIN) most HPV-cancers are preventable with screening and targeted treatment of disease. Pre-transplant vaccination of age-eligible kidney transplant recipients is otherwise ideal.
[Mh] MeSH terms primary: Anus Neoplasms/virology
Cervical Intraepithelial Neoplasia/virology
Graft Rejection/prevention & control
Immunosuppressive Agents/adverse effects
Kidney Failure, Chronic/surgery
Kidney Transplantation
Papillomavirus Infections/chemically induced
Uterine Cervical Neoplasms/virology
[Mh] MeSH terms secundary: Anus Neoplasms/diagnosis
Anus Neoplasms/prevention & control
Anus Neoplasms/therapy
Carcinoma in Situ/diagnosis
Carcinoma in Situ/prevention & control
Carcinoma in Situ/therapy
Carcinoma in Situ/virology
Cervical Intraepithelial Neoplasia/diagnosis
Cervical Intraepithelial Neoplasia/prevention & control
Cervical Intraepithelial Neoplasia/therapy
Early Detection of Cancer
Female
Humans
Male
Papanicolaou Test
Papillomaviridae
Papillomavirus Infections/diagnosis
Papillomavirus Infections/prevention & control
Papillomavirus Infections/therapy
Papillomavirus Vaccines/therapeutic use
Uterine Cervical Neoplasms/diagnosis
Uterine Cervical Neoplasms/prevention & control
Uterine Cervical Neoplasms/therapy
Vaginal Smears
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Immunosuppressive Agents); 0 (Papillomavirus Vaccines)
[Em] Entry month:1801
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE

  4 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29444629
[Au] Autor:Verin R; Cian F; Stewart J; Binanti D; MacNeill AL; Piviani M; Monti P; Baroni G; Le Calvez S; Scase TJ; Finotello R
[Ad] Address:1 Department of Veterinary Pathology and Public Health, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
[Ti] Title:Canine Clitoral Carcinoma: A Clinical, Cytologic, Histopathologic, Immunohistochemical, and Ultrastructural Study.
[So] Source:Vet Pathol;:300985818759772, 2018 Jan 01.
[Is] ISSN:1544-2217
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Vaginal and vulvar tumors are uncommon in dogs. Knowledge of canine primary clitoral neoplasia is restricted to a few case reports, and only carcinomas have been reported. Cytologic and histologic features reported in the literature seem to overlap with those of canine apocrine gland anal sac adenocarcinoma (AGASA). Clinical features also recall those of canine AGASA, such as locoregional metastases and hypercalcemia of malignancy (HM). In this study, 6 cases of primary canine clitoral carcinomas (CCCs), with and without HM, were investigated by means of cytology, histopathology, electron microscopy, and immunohistochemistry for neuroendocrine markers including chromogranin A (CGA), synaptophysin (SYN), neuron-specific enolase (NSE), and S-100. In all 6 tumors, cytologic findings were consistent with malignant epithelial neoplasia of apocrine gland origin. The tumors examined were classified into 3 different histological patterns representing different degrees of differentiation: tubular, solid, and rosette type. Both CGA and SYN were mildly expressed in 2 of 6 tumors, while NSE was consistently expressed in all 6 cases. None of the tumors were S-100 positive. Transmission electron microscopy revealed electron-dense cytoplasmic granules compatible with neuroendocrine granules in all 6 cases. CCCs presented clinicopathologic features resembling AGASAs with neuroendocrine characteristics, and 2 of 6 neoplasms were considered as carcinomas with neuroendocrine differentiation and were positive for 3 neuroendocrine markers. CCCs can often present with HM, and long-term outcome is likely poor. Our study concludes that CCC seems to be a rare tumor, but it might be underestimated because of the overlapping features with AGASA. Further studies should aim to define the true incidence of this disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180215
[Lr] Last revision date:180215
[St] Status:Publisher
[do] DOI:10.1177/0300985818759772

  5 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29439180
[Au] Autor:Chang HA; Armenian SH; Dellinger TH
[Ad] Address:From the Department of Population Sciences, Division of Outcomes Research, and Department of Surgery, Division of Gynecologic Surgery, City of Hope National Medical Center, Duarte, California.
[Ti] Title:Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation.
[So] Source:J Natl Compr Canc Netw;16(2):211-218, 2018 Feb.
[Is] ISSN:1540-1413
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Hematopoietic cell transplantation (HCT) results in long-term survival (≥10 years) in 85% of patients who survive transplant-related complications within the first 2 years posttransplant. Transplant survivors, however, are at an increased risk of chronic health conditions compared with the general population, including the emergence of secondary malignant neoplasms. In particular, female transplant survivors may face a greater risk of lower genital tract (cervical, vulvar, or vaginal) neoplasms due to chronic immune dysregulation in the peritransplant and posttransplant environment. Persistent immune suppression may facilitate the carcinogenesis of human papillomavirus (HPV), the causative agent of nearly all cervical cancers and most vulvar and vaginal cancers. Nevertheless, the risk of these cancers has not been sufficiently quantified in female transplant survivors. Small clinical studies have shown that the rate of cervical cytological abnormalities increases after allogeneic HCT, but large population-based studies have not consistently demonstrated an increased risk of secondary cervical cancer after transplant compared with the general population; the risk of developing secondary vulvar or vaginal cancer after transplant remains unclear. A better understanding of the natural history of HPV-associated lower genital tract neoplasms and their transplant-related risk factors would help delineate optimal long-term follow-up protocols in this population. In this systematic review, we summarize the current literature on this topic and discuss the implications for cervical cancer screening and vaccination in female transplant recipients.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[St] Status:In-Data-Review
[do] DOI:10.6004/jnccn.2018.7005

  6 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29434343
[Au] Autor:Goyal A; Zhang G; Yang B
[Ad] Address:Weill Cornell Medicine, New York Presbyterian Hospital, 525 East 68th Street, F766, New York, NY, 10065, USA.
[Ti] Title:Differential expression patterns of GATA3 in usual and differentiated types of vulvar intraepithelial neoplasia: potential diagnostic implications.
[So] Source:Mod Pathol;, 2018 Feb 13.
[Is] ISSN:1530-0285
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The two main precursors of vulvar squamous cell carcinoma, usual and differentiated vulvar intraepithelial neoplasia (VIN), have distinctive etiology, pathogenesis, and natural history. Usual type VIN is often associated with high-risk HPV and differentiated VIN has de novo p53 genetic alterations that are unrelated to HPV infection. GATA-binding protein 3 (GATA3) is a tumor suppressor that shows increased expression in several types of human malignancies including breast and bladder carcinomas. Little is known regarding the expression of GATA3 in vulvar squamous neoplasms. We have systematically examined the expression of GATA3 in 119 vulvar lesions and neoplasms including 20 cases of lichen sclerosus, 12 cases of lichen simplex chronicus, 30 cases of usual type VIN, 34 cases of differentiated VIN, and 23 cases of squamous cell carcinoma. Similar to adjacent non-neoplastic epidermis, moderate to strong GATA3 expression was retained in all cases of lichen sclerosus, lichen simplex chronicus, and usual type VIN. However, in comparison, the GATA3 immunostaining pattern in differentiated VIN was distinct. Partial/complete loss of GATA3 expression in the basal layer with or without loss in the parabasal layer was observed in 30/34 (88%) of differentiated VIN cases. Significant loss of GATA3 expression was also observed in all (7/7) squamous cell carcinomas associated with usual type VIN and in 13/16 (81%) of those associated with differentiated VIN. There was no significant correlation between loss of GATA3 expression and overexpression of p53 in differentiated VIN. Our study shows that loss of GATA3 expression is seen in the vast majority (87%) of vulvar squamous cell carcinomas. Downregulation of GATA3 may be an early event during tumorigenesis in differentiated VIN but not in HPV-related usual type VIN. Our data suggests that application of GATA3 immunohistochemistry along with p53 may be a useful tool in facilitating the accurate diagnosis of VIN.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[St] Status:Publisher
[do] DOI:10.1038/s41379-018-0021-y

  7 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29427549
[Au] Autor:Anastasi E; Filardi T; Tartaglione S; Lenzi A; Angeloni A; Morano S
[Ad] Address:Department of Molecular Medicine, University "Sapienza", Viale Regina Elena 324, 00161 Rome, Italy, Phone: +39 064472347, Fax: +39 064478381.
[Ti] Title:Linking type 2 diabetes and gynecological cancer: an introductory overview.
[So] Source:Clin Chem Lab Med;, 2018 Feb 10.
[Is] ISSN:1437-4331
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Type 2 diabetes (T2D) is a chronic disease with a growing prevalence and a leading cause of death in many countries. Several epidemiological studies observed an association between T2D and increased risk of many types of cancer, such as gynecologic neoplasms (endometrial, cervical, ovarian and vulvar cancer). Insulin resistance, chronic inflammation and high free ovarian steroid hormones are considered the possible mechanisms behind this complex relationship. A higher risk of endometrial cancer was observed in T2D, even though this association largely attenuated after adjusting for obesity. A clear relationship between the incidence of cervical cancer (CC) and T2D has still not be determined; however T2D might have an impact on prognosis in patients with CC. To date, studies on the association between T2D and ovarian cancer (OC) are limited. The effect of pre-existing diabetes on cancer-specific mortality has been evaluated in several studies, with less clear results. Other epidemiological and experimental studies focused on the potential role of diabetes medications, mainly metformin, in cancer development in women. The correct understanding of the link between T2D and gynecologic cancer risk and mortality is currently imperative to possibly modify screening and diagnostic-therapeutic protocols in the future.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[St] Status:Publisher

  8 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27777126
[Au] Autor:Luxembourg A; Kjaer SK; Nygard M; Ellison MC; Group T; Marshall JB; Radley D; Saah A
[Ad] Address:Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: alain_luxembourg@merck.com.
[Ti] Title:Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
[So] Source:Contemp Clin Trials;52:54-61, 2017 01.
[Is] ISSN:1559-2030
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The 9-valent human papillomavirus (HPV) (9vHPV) vaccine targets four HPV types (6/11/16/18) also covered by the quadrivalent HPV (qHPV) vaccine and five additional types (31/33/45/52/58). Vaccine efficacy to prevent HPV infection and disease was established in a Phase III clinical study in women 16-26years of age. A long-term follow-up (LTFU) study has been initiated as an extension of the Phase III clinical study to assess effectiveness of the 9vHPV vaccine up to at least 14years after the start of vaccination. It includes participants from Denmark, Norway and Sweden and uses national health registries from these countries to assess incidence of cervical pre-cancers and cancers due to the 7 oncogenic types in the vaccine (HPV 16/18/31/33/45/52/58). Incidences will be compared to the estimated incidence rate in an unvaccinated cohort of similar age and risk level. This LTFU study uses a unique design: it is an extension of a Phase III clinical study and also has elements of an epidemiological study (i.e., endpoints based on standard clinical practice; surveillance using searches from health registries); it uses a control chart method to determine whether vaccine effectiveness may be waning. Control chart methods which were developed in industrial and manufacturing settings for process and production monitoring, can be used to monitor disease incidence in real-time and promptly detect a decrease in vaccine effectiveness. Experience from this innovative study design may be applicable to other medicinal products when long-term outcomes need to be assessed, there is no control group, or outcomes are rare.
[Mh] MeSH terms primary: Cervical Intraepithelial Neoplasia/prevention & control
Immunogenicity, Vaccine
Papillomavirus Infections/prevention & control
Papillomavirus Vaccines/therapeutic use
Precancerous Conditions/prevention & control
Uterine Cervical Neoplasms/prevention & control
[Mh] MeSH terms secundary: Adolescent
Adult
Cervical Intraepithelial Neoplasia/epidemiology
Cervical Intraepithelial Neoplasia/virology
Clinical Trials, Phase III as Topic
Denmark/epidemiology
Female
Follow-Up Studies
Humans
Incidence
Norway/epidemiology
Papillomavirus Infections/epidemiology
Papillomavirus Infections/virology
Papillomavirus Vaccines/immunology
Precancerous Conditions/epidemiology
Precancerous Conditions/virology
Randomized Controlled Trials as Topic
Sweden/epidemiology
Treatment Outcome
Uterine Cervical Neoplasms/epidemiology
Uterine Cervical Neoplasms/virology
Vaginal Neoplasms/epidemiology
Vaginal Neoplasms/prevention & control
Vaginal Neoplasms/virology
Vulvar Neoplasms/epidemiology
Vulvar Neoplasms/prevention & control
Vulvar Neoplasms/virology
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Papillomavirus Vaccines)
[Em] Entry month:1712
[Cu] Class update date: 180209
[Lr] Last revision date:180209
[Js] Journal subset:IM
[Da] Date of entry for processing:161108
[St] Status:MEDLINE

  9 / 7971 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29268072
[Au] Autor:Moreira-Barros J; Huang KG
[Ad] Address:Department of Obstetrics and Gynecology. Hospital Pedro Hispano. Matosinhos. Portugal.
[Ti] Title:Metástase Vulvar do Carcinoma de Células Escamosas do Colo do Útero.
[So] Source:Acta Med Port;30(10):757, 2017 10 31.
[Is] ISSN:1646-0758
[Cp] Country of publication:Portugal
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180201
[Lr] Last revision date:180201
[St] Status:In-Process
[do] DOI:10.20344/amp.9414

  10 / 7971 MEDLINE  
              first record previous record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 29186258
[Au] Autor:Campaner AB; Fernandes GL; Cardoso FA; Veasey JV
[Ad] Address:Department of Gynecology and Obstetrics at Irmandade da Santa Casa de Misericórdia de São Paulo - São Paulo (SP), Brazil.
[Ti] Title:Vulvar melanoma: relevant aspects in therapeutic management.
[So] Source:An Bras Dermatol;92(3):398-400, 2017 May-Jun.
[Is] ISSN:1806-4841
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:Cancer of the vulva accounts for at least 1% of malignant neoplasms among women. Although rare, vulvar melanoma is the second most common histological type of vulvar cancer, representing 7-10% of all malignant vulvar neoplasms. Initial symptoms are non-specific and complete excision of the lesion is indicated in cases with suspected diagnosis. Prognosis of patients with these neoplasms is poor and remains unchanged despite the treatment approach. Hemivulvectomy with lymph node dissection is the current procedure of choice, associated or not with adjuvant therapies. We report two cases of patients presenting with late diagnosed vulvar melanoma and the relevant aspects in their therapeutic management.
[Mh] MeSH terms primary: Melanoma/pathology
Vulvar Neoplasms/pathology
[Mh] MeSH terms secundary: Female
Humans
Melanoma/therapy
Middle Aged
Vulvar Neoplasms/therapy
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1801
[Cu] Class update date: 180131
[Lr] Last revision date:180131
[Js] Journal subset:IM
[Da] Date of entry for processing:171130
[St] Status:MEDLINE


page 1 of 798 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information